Clinical effectiveness and pharmacoeconomic impact of long-acting lipoglycopeptides in a multicenter outpatient day hospital model: a real-world Italian study
Retrospective multicenter study demonstrates clinical non-inferiority and economic efficiency of LALs in adults, indicating a reform in treatment approaches.
Key Points
This research aims to assess the clinical effectiveness and pharmacoeconomic impact of long-acting lipoglycopeptides in outpatient settings.
Conducted a retrospective multicenter study across Italian specialized centers.
Analyzed clinical cure rates and pharmacoeconomic outcomes in patients treated with dalbavancin or oritavancin.
Compared the outpatient Day Hospital model to a Standard of Care inpatient approach for economic evaluations.
Achieved an overall clinical success rate of 86.9% without a significant difference in registered versus off-label infections.
Generated direct healthcare savings exceeding €629,000 by reducing inpatient bed days and preventing lost workdays.
Avoided 7.2 healthcare-associated infections, translating to additional savings in management costs.